Sabra Healthcare REIT (SBRA) Stock: Buy, Sell, or Hold?
SBRA - Sabra Healthcare REIT, Inc.
$19.20
-0.52 (-2.64%)
▼
5d:
-2.88%
30d:
-8.31%
90d:
-4.76%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When SBRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SBRA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SBRA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$39.43
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$24.49
21.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SBRA is currently trading at $19.20, which is considered oversold relative to its 30-day fair value range of $19.81 to $20.81. The stock's valuation (Forward PE: 23.7) is in line with its historical norms (25.9). Remarkably, the market is currently pricing in an annual earnings decline of 3.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SBRA is in a strong uptrend. The price is currently testing key support at $19.14. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SBRA scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.79 (+18.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SBRA is in a strong uptrend. The price is currently testing key support at $19.14. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SBRA scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.79 (+18.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$19.81 -
$20.81
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (27/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($22.79)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$19.81 -
$20.81
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$19.15
Resistance Level
$20.10
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.70
Wall Street Target
$22.79
(+18.7%)
Revenue Growth (YoY)
25.3%
Earnings Growth (YoY)
-5.6%
Profit Margin
7.6%
Valuation Discount vs History
-3.0% cheaper
PE vs Historical
23.7 vs 25.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.0%
(market-implied from PE analysis)
1-Year Target
$18.62
(-3%)
2-Year Target
$18.07
(-6%)
3-Year Target
$17.52
(-9%)
3-Yr Target (if PE normalizes)
(PE: 24→26)
$19.15
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.7, Growth: 67.2%)
$64.80
(+238%)
Base:
(SPY PE: 20.4, Growth: 67.2%)
$55.77
(+191%)
Bear:
(PE: 17.3, Growth: 67.2%)
$47.40
(+147%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Forward PE: 32.15 | Forward EPS (Implied): $0.60
Bull Case
$23.18
(+21%)
Analyst growth 15.0%, PE expands to 33.8
Base Case
$19.20
(0%)
Market implied 0.0%, PE stable at 32.2
Bear Case
$14.69
(-24%)
Severe decline -15.0%, PE contracts to 28.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.7 to 25.9
Stabilization Target:
$20.98
(+9.3%)
PE Expansion Potential:
+9.3%
Share & Embed Analysis
Last updated: October 02, 2026 12:48 AM ET
Data refreshes hourly during market hours. Next update: 1:48 AM
Data refreshes hourly during market hours. Next update: 1:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SBRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated REIT - Healthcare Facilities Stocks
Top-rated stocks in REIT - Healthcare Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
WELL
Welltower Inc |
STRONG BUY
20 analysts |
$262 | 60 HOLD |
|
VTR
Ventas Inc |
STRONG BUY
20 analysts |
$102 | 53 HOLD |
|
DOC
Healthpeak Properties Inc |
STRONG BUY
20 analysts |
$23 | 35 SELL |
|
AHR
American Healthcare REIT… |
STRONG BUY
9 analysts |
$64 | 54 HOLD |
|
STRW
Strawberry Fields REIT L… |
STRONG BUY
7 analysts |
$16 | 44 HOLD |
